It depends on the reason why patients are making that choice. If they have researched their options and discussed their decision with a qualified surgeon before making their decision, and they still feel that a GLP-1 medication is best for them, thats patient-centered care, according to DeBarros
hertz : The frequency with which something (such as a wavelength) occurs, measured in the number of times the cycle repeats during each second of time
Wegovy has been associated with modest increases in heart rate in clinical trials (typically 14 beats per minute on average, according to the SmPC)
This is a characteristic of the drug itself, not an artifact of one trial
Both sexes are subject to the neurochemical effects on reward pathways, but hormonal factors create different clinical presentations
Therefore, the trophic effects of GLP-1R signaling appear to target the distal gut (small intestinal length, large bowel length and weight) (Koehler et al., 2015)